BioOra and Wellington Zhaotai Expand CAR T-Cell Therapy Globally
BioOra Limited and Wellington Zhaotai Therapies Limited have signed a Heads of Terms agreement to expand the global reach of their CAR T-cell therapy. This agreement grants BioOra the rights to develop and commercialize Wellington Zhaotai's third-generation anti-CD19 CAR T-cell therapy, WZTL-002, outside of China and India. The therapy targets haematological malignancies and autoimmune diseases. BioOra's automated manufacturing process, utilizing the Cocoon platform, aims to make CAR T-cell production more consistent and cost-effective, addressing key barriers to accessibility. 
